Yunkang Group Limited (HK:2325)
:2325
Want to see HK:2325 full AI Analyst Report?
Top Page
Yunkang Group Limited
(2325)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.76
▼(-23.03% Downside)
Action:ReiteratedDate:04/30/26
The score is held back most by very weak valuation (P/E ~183) and a broadly bearish price trend (trading below key moving averages with negative MACD). Financially, strong cash generation and an operating rebound in 2025 help offset multi-year revenue contraction and unstable profitability, resulting in a mid-to-low overall score.
Positive Factors
Cash generation
Consistent positive operating cash flow and a sharp free cash flow increase in 2025 indicate durable internal funding. Reliable cash generation supports capex, working capital and potential debt reduction, reducing reliance on external financing and improving long-term operational resilience.
Negative Factors
Multi-year revenue decline
Persistent top-line contraction over multiple years erodes scale, weakens pricing power and limits ability to invest in growth. A shrinking revenue base makes margin recovery harder to sustain, reduces operating leverage benefits and raises long-term risk to market position and cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent positive operating cash flow and a sharp free cash flow increase in 2025 indicate durable internal funding. Reliable cash generation supports capex, working capital and potential debt reduction, reducing reliance on external financing and improving long-term operational resilience.
Read all positive factors
Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$515.64M
Dividend Yield2.15%
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue Growth-15.53%
EPS GrowthN/A
CountryHK
Employees1,249
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-1.22
Shares Outstanding621,250,500
10 Day Avg. Volume4,171,850
30 Day Avg. Volume1,613,200
Financial Highlights & Ratios
PEG Ratio-1.82
Price to Book (P/B)0.45
Price to Sales (P/S)0.89
P/FCF Ratio2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Yunkang Group Limited Business Overview & Revenue Model
Company Description
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the e...
Yunkang Group Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
53
Neutral
Cash Flow
69
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 645.16M | 585.82M | 711.88M | 891.50M | 3.76B | 1.70B |
| Gross Profit | 189.24M | 178.09M | 211.07M | 325.79M | 1.47B | 1.07B |
| EBITDA | -597.39M | 90.04M | -668.52M | 25.07M | 569.53M | 496.15M |
| Net Income | -720.89M | 2.84M | -791.68M | -102.26M | 377.31M | 380.93M |
Balance Sheet | ||||||
| Total Assets | 3.06B | 2.74B | 3.23B | 4.53B | 5.51B | 3.00B |
| Cash, Cash Equivalents and Short-Term Investments | 1.69B | 1.77B | 1.73B | 1.87B | 1.43B | 800.70M |
| Total Debt | 1.02B | 692.60M | 1.07B | 1.39B | 786.12M | 362.02M |
| Total Liabilities | 1.96B | 1.57B | 2.08B | 2.41B | 2.66B | 1.23B |
| Stockholders Equity | 1.10B | 1.16B | 1.14B | 2.33B | 2.84B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | 161.48M | 246.23M | 228.38M | 271.63M | -239.05M | 141.06M |
| Operating Cash Flow | 171.25M | 301.61M | 258.84M | 333.84M | 130.33M | 413.26M |
| Investing Cash Flow | 63.78M | 313.56M | 354.02M | -153.94M | -1.25B | 310.72M |
| Financing Cash Flow | -202.32M | -414.36M | -535.63M | 276.48M | 1.10B | -215.32M |
Yunkang Group Limited Technical Analysis
Negative
0.99
Price Trends
0.81
Negative
0.90
Negative
1.62
Negative
Market Momentum
-0.01
Positive
40.74
Neutral
17.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Negative. The current price of 0.99 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.81, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.74 is Neutral, neither overbought nor oversold. The STOCH value of 17.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2325.
Yunkang Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$1.50B | 10.51 | 5.64% | 1.20% | 1.75% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$515.64M | ― | -34.57% | 2.15% | -15.53% | ― | |
42 Neutral | HK$3.15B | -1.03 | -6.63% | ― | -4.38% | ― | |
41 Neutral | HK$1.17B | -11.46 | -1.97% | ― | 10.88% | 90.15% |
* Healthcare Sector Average
HK:2325
Yunkang Group Limited
0.81
-2.07
-71.88%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.37
-2.08
-46.74%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
11.41
-0.99
-7.98%
HK:3309
C-MER Eye Care Holdings Limited
1.21
-0.48
-28.40%
HK:6667
Mega Genomics Limited
7.15
-0.05
-0.69%
Yunkang Group Limited Corporate Events
Yunkang Group to Overhaul Constitution to Meet Updated Hong Kong Listing Rules
Mar 31, 2026
Yunkang Group Limited plans to replace its existing amended and restated memorandum and articles of association with a second amended and restated version, updating its constitutional documents to align with the latest Hong Kong Listing Rules. The...
Yunkang Returns to Profit in 2025 Despite Revenue Decline
Mar 31, 2026
Yunkang Group Limited reported a decline in revenue for the year ended December 31, 2025, with total revenue falling 15.5% year on year to RMB601.4 million, mainly due to a 28.1% drop in diagnostic outsourcing services and softer demand across its...
Yunkang Group Sets March 30 Board Meeting to Approve 2025 Results
Mar 18, 2026
Yunkang Group Limited has scheduled a board meeting for March 30, 2026, to review and approve the annual results for the financial year ended December 31, 2025. The board will also decide on the publication of these results, which are important fo...
Yunkang forecasts 2025 profit after major turnaround in costs and receivables
Mar 6, 2026
Yunkang Group Limited has issued a positive profit alert, indicating it expects to swing to a net profit of between RMB3.2 million and RMB9.8 million for 2025, from a net loss of about RMB793.2 million in 2024. The turnaround comes despite pressur...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.